{
  "id": 20527518,
  "title": "FDA approves new drug for advanced head and neck squamous cell carcinoma",
  "url": "https://urgent.news/2026/11/18/fda-approves-new-drug-for-advanced-head-and-neck-squamous-cell",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-18T01:20:05.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-11-fda-drug-advanced-neck-squamous.html"
  },
  "original_language": "en",
  "account": "The U.S. Food and Drug Administration has granted approval to Janssen Biotech's Rybrevant Faspro, a new drug for treating adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that has progressed after receiving platinum-based chemotherapy and immunotherapy. This marks the first approval in ten years for a medication addressing recurrent or metastatic HNSCC in patients who have undergone platinum-based chemotherapy. Rybrevant Faspro is not intended for the treatment of oropharyngeal squamous cell carcinoma linked to human papillomavirus.\n\nThe approval is based on a clinical trial involving 102 patients with recurrent or metastatic HNSCC. The drug demonstrated an overall response rate of 42%, compared to 20% for existing therapies. Among those who responded to Rybrevant Faspro, 56% maintained a response lasting six months or longer. Angelo De Claro, M.D., director of the FDA Oncology Center of Excellence, highlighted that this approval represents a significant advancement for patients with HNSCC, a disease that has historically faced limited treatment options and poorer outcomes.",
  "summary": "The U.S. Food and Drug Administration has approved Janssen Biotech's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed during or after receipt of platinum-based chemotherapy and immunotherapy.",
  "key_points": [
    "FDA approves Rybrevant Faspro for advanced HNSCC",
    "42% overall response rate in clinical trial",
    "Significant advancement for HNSCC patients"
  ],
  "editors_take": "This approval ends a decade-long stagnation in therapeutic options for patients with advanced head and neck cancers who have already failed standard platinum-based chemotherapy and immunotherapy treatments.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}